Navigation Links
Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
Date:7/20/2009

KING OF PRUSSIA, Pa., July 20 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the initiation of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the dose escalation and safety study in healthy volunteers are expected before the end of the year.

"Based on extensive work with the predecessor compound, we believe CPSI-2364 has the potential to revolutionize the treatment of TNF-mediated diseases, such as Crohn's, rheumatoid arthritis and psoriasis. We are excited to be advancing it into the clinic," said Dennis F. Willson, president and CEO of Cytokine PharmaSciences. "As a small molecule, CPSI-2364 is less expensive to produce than biologics and can be given orally. Moreover, because it is not a protein, CPSI-2364 is not expected to generate antibodies that could neutralize its activity and result in loss of efficacy over time."

CPSI-2364 is a chemically-modified form of the synthetic guanylhydrozone, semapimod. Semapimod has been shown to inhibit the signal transduction pathways that lead to the production of nitric oxide and important pro-inflammatory cytokines, including TNF-alpha, IL-1, IL-6, and IL-8. Semapimod has demonstrated activity in multiple animal models of inflammation and autoimmune disease, proof-of-concept studies that led to human clinical trials. An intravenous formulation of semapimod was shown to have significant anti-inflammatory activity in Phase II clinical trials in Crohn's disease, psoriasis and ERCP-induced pancreatitis. However, that formulation caused dose-limiting local reactions, such as phlebitis. To overcome this problem, the Company developed CPSI-2364, a more soluble salt of semapimod that makes oral dosing possible. Animal models have confirmed the oral activity of CPSI-2364.

About Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. is a specialty pharmaceutical company engaged in developing anti-inflammatory and autoimmune therapeutics. The Company is headquartered in King of Prussia (near Philadelphia), Pennsylvania. A wholly owned subsidiary, Controlled Therapeutics (Scotland) Limited (CT), is located in East Kilbride (near Glasgow). CT develops and manufactures controlled-release drug delivery products and has a strong focus in the area of women's health, including manufacturing the successful cervical ripening product, the Cervidil(R) vaginal insert (Propess(R) in Europe and elsewhere). Cytokine PharmaSciences has three products in clinical development and employs 70 people at its locations in the U.S. and Scotland. For more information, please visit the company's websites at www.cytokinepharmasciences.com and www.ctscotland.com.


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 EnvoyHealth, a Diplomat company, has partnered ... for CleverCap LITE, a technology designed to improve patient ... innovative health technology solutions and services that help track ... CleverCap LITE offers medication monitoring and control ... Records date and ...
(Date:7/26/2017)... , July 27, 2017  Radium Medical Aesthetics, a leading medical ... to delay aging by effectively addressing several skin conditions from the ... to become rougher and more fragile. The skin becomes more transparent ... exposure to the harmful UV rays from the sun contributes to ... ...
(Date:7/25/2017)... Curing Stomach Cancer (DDF) is excited to host its 3 rd Annual ... Spa in Weston, Florida beginning at 10:30 a.m.   ... Luncheon Committee Co-chair and DDF Board ... Sabrina Kurzman. ... Aura Morales-Guzman, Angela Perez, DDF Board Member John Nash (of 2016 ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test Now® ... company ranked #4429 on the newly released, 36th annual Inc. 5000 , the ... look at the most successful companies within the American economy’s most dynamic segment — ...
(Date:8/16/2017)... ... , ... In a recent survey, eighty-two percent of women reported having cellulite, ... can't always be eliminated by diet and exercise alone, and now for the first ... Dr. Kenneth Rothaus has recently added Cellulaze™ to his practice in New ...
(Date:8/16/2017)... ... August 16, 2017 , ... Maury Regional Health has announced ... draws. By broadly deploying AccuVein devices, Maury Regional Medical Center is making vein visualization ... out of a needle stick and more importantly, helps our staff members locate a ...
(Date:8/16/2017)... Ca (PRWEB) , ... August 16, 2017 , ... ... engineers, and scientists from around the world, is excited to announce Andrew Ly as ... in his academic pursuits, covering textbook costs. , Ly, who is in his ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
Breaking Medicine News(10 mins):